About Us Weisberg ConsulGng derives its experGse with an extensive experience in business and corporate development as well as building brands and companies both in the United States as well as internaGonal markets. Structured along the lines of a pharmaceuGcal company, we have four areas of specialty: Corporate and Business Development Market intelligence Brand management Brand and corporate strategy. The integraGon of these specialGes allows for the development of stakeholder-‐ driven and fact-‐based strategies. This approach has repeatedly generated substanGal and sustainable growth, even in mature markets – providing clarity, control and conﬁdence in strategy to improve both brand and business performance.
Key Transactions M&A/Out-‐licensing Deals IniGated and closed on a $105 million transacGon with Cowen Healthcare Royalty in which we moneGzed the royalty stream of a key product NegoGated several oﬀ-‐shore licensing deals on several key products Raised iniGal funding for the development of a new company involved in an innovaGve cardiovascular therapeuGc. Led acquisiGon of a business from Baxter Healthcare enabling company to be ﬁrst entrant into $400 million US market. Generated proceeds of $30 million in IPO providing capital for growth and product development. Concluded an iniGal round of funding with a mid-‐west venture capital group for $3.5 million; leading the eﬀorts to raise an addiGonal $9 million in a Series A ﬁnancing for a cardiovascular product Out-‐licensed a GI opportunity to a specialty pharmaceuGcal company – Deal Value: $150 million Out-‐licensed an oncology/immune-‐enhancement biologic to a mid-‐sized pharmaceuGcal company – Deal Value: $200 million Divested the viral tesGng business of AvenGs Behring to NaGonal GeneGcs InsGtute, subsidiary of LabCorp
Key Transactions Other Deals IniGated and closed on a partnering arrangement to enhance product development and add new products into the development pordolio Led negoGaGons on the acquisiGon of a cardiovascular opportunity – Deal Value: $500 million Led the development of a global recombinant albumin business valued in excess of $750 million; negoGated out-‐licensing agreements with a number of major pharmaceuGcal companies NegoGated a Licensing Agreement with the leading global medical device company – Deal Value: $650 million NegoGated a Supply and DistribuGon Agreement that resulted a net in excess of $100 million over several years
Key Transactions Other Deals (cont’d) NegoGated a licensing and development agreement with a leading pulmonary delivery device ﬁrm with a deal value of $350 million NegoGated a licensing and development agreement for a specialty medical product valued at $500 million NegoGated agreement for the distribuGon of acquired products in US. Developed exclusive global contract manufacturing agreement with European company, avoiding expense of $75 million for construcGon of manufacturing facility. Managed transfer of proprietary technology to European manufacturer, completed in less than twelve months at 75% of originally budgeted cost. Led the negoGaGon of a License Agreement for a monoclonal-‐based pladorm opportunity Deal Value: $350 million
The Licensing Process Our goal is to idenGfy licensors for hard to license products. This is done by conducGng the following analyses: What strategic gaps in pipeline or pordolio need to be ﬁlled to by the candidate licensor? What are the underlying dynamics of the product to be licensed? How will potenGal licensors relate to the product? Which markeGng levers will drive growth the product?
The Licensing Process Our approach will provide a structural understanding of the product to be licensed. We structure, source and analyze informaBon in a manner that provides a 360o perspecBve of the product. Such a perspecBve drives decision making diﬀerently. We will provide clarity and transparency on brand performance issues as well as provide insight into untapped sources of business. The success of any brand is based on a number of interconnected elements. We will idenBfy which of these levers drives performance of your brand and provides eﬀecBve control over its execuBon. Our iteraBve and highly dynamic modeling approach enables you to explore, test and analyze a range of plausible strategic scenarios in a risk-‐free environment. Our custom built tools provide a high degree of conﬁdence in the chosen strategy for building superior brand performance.